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Binding of cGMP to the GAF-B domain of phosphodi-
esterase 2A allosterically activates catalytic activity. We
report here a series of mutagenesis studies on the GAF-B
domain of PDE2A that support a novel mechanism for
molecular recognition of cGMP. Alanine mutations of
Phe-438, Asp-439, and Thr-488, amino acids that interact
with the pyrimidine ring, decrease cGMP affinity
slightly but increase cAMP affinity by up to 8-fold. Each
interaction is required to provide for cAMP/cGMP spec-
ificity. Mutations of any of the residues that interact
with the phosphate-ribose moiety or the imidazole ring
abolish cGMP binding. Thus, residues that interact with
the pyrimidine ring collectively control cAMP/cGMP
specificity, whereas residues that bind the phosphate-
ribose moiety and imidazole ring are critical for high
affinity binding. Similar decreases in binding were
found for mutations made in a bacterially expressed
GAF-A/B plus catalytic domain construct. Because these
constructs had very high catalytic activity, it appears
that these mutations did not cause a global denatur-
ation. The affinities of cAMP and cGMP for wild-type
GAF-B alone were 4-fold greater than for the holoen-
zyme, suggesting that the presence of neighboring do-
mains alters the conformation of GAF-B. More impor-
tantly, the PDE2A GAF-B, GAF-A/B, GAF-A/BC
domains, and holoenzyme all bind cGMP with much
higher affinity than has previously been reported. This
high affinity suggests that cGMP binding to PDE2
GAF-B activates the enzyme rapidly, stoichiometrically,
and in an all or none fashion, rather than variably over
a large range of cyclic nucleotide concentrations.
Eleven different phosphodiesterase (PDE)1 families, each
containing multiple genes, have been described and differ in
substrate specificity, regulatory properties, inhibitor profiles,
and tissue distribution (1). The cGMP-stimulated PDEs
(PDE2s) are one of three families of PDEs (PDE2s, PDE5s, and
PDE6s) that are confirmed to contain allosteric cyclic nucleo-
tide binding sites that bind cGMP (2). Two other cGMP PDE
families, PDE10A and PDE11A, have homologous regulatory
segments (3, 4). In PDE2A, cGMP binding to an allosteric site
stimulates catalytic activity, which has numerous physiological
consequences in vivo. For example, atrial natriuretic peptide
stimulation of cGMP production and subsequent activation of
PDE2A in the adrenal cortex decreases aldosterone secretion,
thereby possibly mediating the effect of the hormone on fluid
volume (5).
Previous studies have shown that 1 mol of cGMP is bound
per PDE2 monomer (6). Each PDE2A monomer contains a
tandem pair of domains (GAF-A and GAF-B) that are now
known to be part of a large family of small molecule binding
domains called GAF domains (Fig. 1) (7, 8). GAF domains were
first recognized by sequence homology in cGMP-specific PDEs,
bacterial adenylyl cyclases, and FhlA, a bacterial transcription
modulator; they have now been shown to exist in over 1360
different proteins in organisms ranging from humans to
sponges (7, 8). Cyclic GMP appears only to bind GAF-B in
PDE2A (9) and GAF-A in PDE5A (10). Recently, a mammalian
PDE2 GAF domain has been shown capable of activating the
adenylyl cyclase cyaB1 of Anabaena, a species of cyanobacte-
rium, demonstrating that the function of these domains has
been conserved in species separated by over 2 billion years of
evolution (11).
The GAF domains of cGMP-regulated PDEs and Anabaena
adenylyl cyclase cyaB1 are distinguished from most other GAF
domains by the presence of a conserved NKXnFX3DE (NKFDE)
motif (12). The NKFDE motif is conserved in almost all PDE
GAF domains and has been proposed to be involved directly in
cGMP binding (13–15). In the bovine PDE5A holoenzyme, sub-
stitution of Asn-276, Lys-277, or Asp-289 with alanine in the
NKFDE motif of the GAF-A domain has been reported to in-
crease the apparent KD for cGMP from 1.3 M to between 12
and 60 M (13). In the human PDE5A GAF-A domain expressed
alone, however, mutation of the aspartate in the NKFDE motif
to alanine (D299A) only weakened binding by 3-fold from 27 to
78 nM (16). The high affinity binding for the human isoform was
attributed to the absence of the GAF-B and N-terminal do-
mains of PDE5A in the expression construct (16).
In the crystal structure of PDE2A GAF-A/B, the NKFDE
motif residues of GAF-B are not in contact with cGMP (9). On
the contrary, they are at the other side of a  sheet making up
the floor of the cGMP binding pocket of the GAF-B domain, far
from the cGMP binding site (Fig. 2A) (9). The crystal structure
of PDE2A GAF-A/B also shows continuous electron density
between the lysine and aspartate in this motif, which may
indicate that a salt bridge forms between these residues (9).
The ability of cAMP- and cGMP-dependent kinases, cyclic
nucleotide-gated channels, and cyclic nucleotide phosphodies-
terases to discriminate between cAMP and cGMP is an integral
part of how these signaling pathways react to cellular stimuli.
A single amino acid has been shown to be critical in controlling
the specificity of cyclic nucleotide binding to cAMP- and cGMP-
dependent kinases, cyclic nucleotide gated channels, and ad-
enylyl and guanylyl cyclases (17–19). Many high affinity gua-
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nine nucleotide-binding proteins utilize the carboxylate group
of an aspartate or glutamate residue to bind both the N-1 and
N-2 of cGMP (17, 20–23). However, there have been relatively
few studies probing these details in PDEs. In one study, mu-
tagenesis of Asp-289 within the cGMP binding GAF domain of
PDE5A was shown to influence cAMP/cGMP specificity when
the pH was lowered from 9.5 to 5.2 (24). Otherwise, little is
known about the molecular determinants of substrate specific-
ity for any GAF domain-containing protein.
The amino acid residues in close contact with the nucleotide
have been revealed in the crystal structures of several nucle-
otide-binding proteins in complex with substrates or analogs
(25–28). However, it also is known that the crystal structure of
a complex often does not adequately characterize the relative
importance of each close residue for nucleotide binding or nu-
cleotide discrimination. In the present study, we used the re-
cently determined 2.9-Å crystal structure of PDE2A GAF-A/B
bound to cGMP (9) as a guide for mutagenesis to determine to
what extent various residues lining the GAF-B domain pocket
determine cAMP and cGMP binding affinity and specificity.
EXPERIMENTAL PROCEDURES
Materials—[8-3H]cGMP and [5,8-3H]cAMP were purchased from
PerkinElmer Life Sciences. cAMP (sodium salt), cGMP (sodium salt),
epoxy-activated Sepharose 6B, pepstatin A, phenylmethylsulfonyl flu-
oride, dithiothreitol, and isopropyl--D-thiogalactopyranoside were ob-
tained from Sigma.
Cloning and Site-directed Mutagenesis—cDNA for mouse PDE2A2
GAF-A (residues 206–386), GAF-B (residues 398–553), GAF-A/B plus
catalytic domain (GAF-A/BC) (residues 207–933) were cloned into a
derivative of the pMW172 vector (Fig. 1) (29). GAF-A/B (residues 207–
566) had previously been cloned into the same vector (9). The vector-
derived sequence LE(H6) was appended to the C terminus, and a Met to
the N terminus. The QuikChange site-directed mutagenesis kit (Strat-
agene) was used to make point mutations in the pMW172 clone accord-
ing to the protocol from Stratagene. Mutagenic oligonucleotides (see
Table I) were ordered from Integrated DNA Technologies (Coralville,
IA). Escherichia coli XL-1 blue cells were used for all DNA manipula-
tions. DNA was purified from small scale vector preparations using a
Qiagen Plasmid Mini kit according to the manufacturer’s protocol. DNA
segments subjected to mutagenesis and subcloning reactions were se-
quenced in their entirety to ensure the presence of the desired mutation
and proper in-frame subcloning. The same procedures and oligonucleo-
tides were used to make the PDE2A GAF-A/B plus catalytic domain
constructs (A/BC).
Expression of Wild Type and Mutant PDE2 GAF Domains—Wild-
type and mutant GAF domains were expressed in C41 (30), a derivative
of the E. coli strain BL21(DE3). The mutants were expressed at levels
comparable to that of the wild-type GAF domains (5–7 mg/liter of
culture). Luria broth with 50 g/ml ampicillin was used, and cells were
first grown at 37 °C until A600  0.5. The cells were then induced with
isopropyl--D-thiogalactopyranoside (30 mg/liter) and incubated at
16 °C for 22 h. Cells were disrupted in lysis buffer (100 mM NaCl, 20 mM
Tris, pH 7.5, 1 g/ml leupeptin, 1 g/ml pepstatin A, 1 mM phenylmeth-
ylsulfonyl fluoride, and 1 mM -mercaptoethanol) by microfluidization
(10,000 p.s.i.) (Microfluidics, Newton, MA) (31), and then centrifuged at
16,000  g for 15 min. The supernatant was filtered through Whatman
filter paper and then chromatographed through an epoxy-Sepharose
cGMP affinity column (32). After elution with 1 mM cGMP (200 mM
NaCl, 20 mM Tris, pH 7.5, 0.1 mM EDTA, and 1 mM -mercaptoethanol)
and concentration using a Centriplus centrifugal filter (Amicon), aggre-
gated protein was removed by gel filtration on Superose 12 (Amersham
Biosciences) in 100 mM NaCl, 20 mM Tris, pH 7.5, 0.5 mM EDTA, 1 mM
-mercaptoethanol, and 1 mM dithiothreitol.
All the mutated proteins that were purified on the cGMP affinity
column migrated on the gel with essentially the same mobility as that
of the wild-type GAF domain. Thus, we assume that these single nu-
cleotide changes did not substantially affect transcription, translation,
or folding of the protein and that the cGMP binding affinity changes
were not due to global effects on protein folding.
Mutant GAF proteins that did not bind to the cGMP affinity column
were purified using Talon metal affinity resin (Clontech) using the
C-terminal His6 tag of the protein. Cells were disrupted as above, and
the supernatant incubated for 1 h at 4 °C with Talon resin (5 ml of
resin/liter of culture) pre-washed three times at 700  g in wash buffer
(100 mM NaCl and 20 mM Tris, pH 7.5). After incubation, the resin was
washed three times, transferred to a 20-ml Econo-Pac column (Bio-
Rad), and washed again with 10 bed-volumes of wash buffer. The resin
was then washed once with 10 mM imidazole, and protein was eluted
with 150 mM imidazole in 100 mM NaCl and 20 mM Tris, pH 7.5,
followed by gel filtration on Superose-12. These mutations also probably
do not cause a large global structural change to the protein, because the
mutants were expressed in soluble form and purified as a single sym-
metrical peak of the correct Stoke’s radius over the Superose-12 sizing
columns. In addition, when three of the non-binding GAF-A/BC con-
structs (A459S, K516A, and F522A) were made and tested, all had high
catalytic activity, again suggesting a lack of a large global change in the
protein. More localized domain changes can not, however, be entirely
ruled out without determining the crystal structure of each mutant
protein.
Bovine PDE2A1 holoenzyme was expressed in Sf9 cells infected with
baculovirus (33). Sf9 cells were grown at 27 °C in complete Grace’s
insect medium (Invitrogen) with 10% fetal bovine serum and 50 g/ml
penicillin/streptomycin in spinner flasks (80–90 rpm) and were infected
with 100 ml of virus (at a multiplicity of infection of 10) per liter of
media. At 72 h, the cells were harvested and disrupted by microfluidi-
zation (5,000 p.s.i.) and then centrifuged at 16,000  g for 15 min. The
holoenzyme was purified on an epoxy-Sepharose cGMP affinity column
in the presence of 5 mM EDTA followed by gel filtration on Superose-12
(32).
cGMP Competition Binding Assay—To measure cGMP binding, ni-
trocellulose filter binding assays were conducted in a total volume of 10
ml containing 5 mM Tris, pH 7.5, 25 mM NaCl, 2 mM EDTA, 10 g/ml
bovine serum albumin, and 0.5 nM to 100 M [8-3H]cGMP (100 l of
6000 cpm/pmol [8-3H]cGMP). The reaction was initiated by addition of
GAF protein. Dilutions were made until the concentration of binding
protein was always at least 3-fold less than the determined IC50 value.
Following 1 h of incubation on ice, ammonium sulfate was added to a
final concentration of 1 M. This mixture was filtered through pre-
moistened Millipore HAWP filters (pore size, 0.45 m) and rinsed twice
with a total of 6 ml of ice-cold 1 M ammonium sulfate buffer (20 mM Tris,
pH 7.5, 100 mM NaCl, and 5 mM EDTA). In pilot experiments one molar
ammonium sulfate was found to be sufficient to maximize binding to
each of the wild-type expressed proteins. The filters were dissolved in
Filter Count® (Packard) scintillation mixture and counted with a Pack-
ard 1600 TR liquid scintillation analyzer. The bound protein counts
were corrected by subtraction of nonspecific binding, which was defined
as the [8-3H]cGMP bound in the absence of GAF protein. The data were
subjected to non-linear least squares analysis using Prism (GraphPad
Software) to obtain IC50 values.
Other Methods—Total protein concentrations were determined by
the method of Bradford, using bovine serum albumin as the standard
(Pierce).
RESULTS
Phe-438, Asp-439, and Thr-488 Determine Cyclic Nucleotide
Discrimination—We reasoned that one or more of the residues
that interact with or are near the positions where the structure
of cAMP and cGMP are different should control cyclic nucleo-
tide specificity. Constructs containing mutations of these resi-
FIG. 1. PDE2A holoenzyme and GAF domain proteins. Sche-
matic diagram showing the various constructs generated in this study.
The numbers in parentheses are the residue boundaries of the individ-
ual PDE2A GAF domain constructs.
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dues in PDE2 GAF-A/B were expressed in bacteria and purified
using a cGMP affinity column (Fig. 3). The fact that all could
bind to and be eluted from the affinity column strongly sug-
gests that each could fold properly. To analyze the effects on
substrate selectivity, full IC50 curves for both cGMP and cAMP
were determined for the wild-type and each mutant. The
change in substrate selectivity caused by each mutation is
shown by the ratio of IC50 values for cGMP and cAMP (Table
II). F438A, D439A, and T488A each increased the IC50 for
cGMP about 2-fold relative to wild-type. However, these muta-
tions each decreased the IC50 for cAMP by as much as 8-fold
compared with wild-type (Fig. 4). Therefore, the selectivity
ratio changes by 16-fold. The increased affinity for cAMP also
indicates that these mutations were not generally deleterious
to either the overall structure or to the binding pocket of
PDE2A GAF-B. Furthermore, the results indicate that a major
effect of each mutation is to remove a negative determinant for
cAMP binding. Thus, those residues that determine specificity
within the binding site appear mostly to restrict the access of
cAMP rather than increase the affinity for cGMP.
Asp-439 was replaced with an uncharged asparagine to de-
termine if the carbonyl of the side chain of D439N could form a
FIG. 2. A, PDE2A GAF-B with cGMP bound. The conserved residues of the NKFDE motif are highlighted in yellow. Note that these residues are
not in the cGMP binding pocket. The lysine (K516) and aspartate (D526) form a salt bridge (white dotted line) that is required for binding. cGMP
is highlighted in orange. The figure was constructed using MOLSCRIPT® and RASTER3D. B, close-up view of the cGMP binding site in PDE2A
GAF-B. Shown are nine residues that interact with cGMP in the binding site: six make hydrogen bonds, one base stacks with the guanine ring,
and two make backbone amide contacts. This figure was made with MOLSCRIPT and RASTER3D. C, close interactions between PDE2A GAF-B
and cGMP. The residues interacting with cGMP or HOH are shown. The figure was constructed using LIGPLOT. Carbon, nitrogen, and oxygen
atoms are shown in black, blue, and red, respectively. Likely hydrogen bonds are shown by the dotted green lines.
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similar hydrogen bond to that of Asp-439. We also wanted to
test if the amino group of the side chain could hydrogen bond to
the deprotonated N-1 of cAMP and increase affinity. D439N
has a similar affinity (28  11 nM) for cGMP as wild-type (25 
2 nM) (Table II). This shows that a negatively charged side
chain is not necessary for cGMP specificity. A hydrogen bond
between the Asp-439 or D439N side chain and cGMP may still
be necessary, because D439A has a slightly lower affinity for
cGMP (61  3 nM) than wild-type. As predicted, D439N does
increase the affinity for cAMP (131  27 nM) versus wild-type
(247  14 nM). However, a partial steric clash also is suggested
by the fact that D439A has an apparent affinity of 46  13 nM,
which is higher than wild-type (247  14 nM) or D439N (131 
27 nM). Therefore, the presence of Asp-439 allows for high
affinity cGMP binding, but either the aspartate or asparagine
side chain antagonizes cAMP binding relative to alanine. A
mutation to proline of Asp-439 increases the IC50 for cGMP
(152  31 nM) to the same levels as cAMP (158  32 nM), which
was slightly lower than for wild-type.
Charged, polar, or aromatic substitutions of Phe-438 (F438D,
F438E, F438Q, and F438Y) as well as D439H in PDE2A GAF-B
(Table III) also gave IC50 values that showed weaker cGMP
affinity but enhanced cAMP affinity. As with PDE2A GAF-A/B,
these GAF-B mutants expressed at comparable levels, bound to
a cGMP affinity column, and had an identical mobility on
SDS-PAGE as the wild-type protein, suggesting that they were
correctly folded, full-length, and capable of binding cGMP. The
fact that non-alanine substitutions of Phe-438 and Asp-439
gave similar affinities as the alanine mutations argues that
both the phenylalanine and aspartate residues are unfavorable
for cAMP binding, rather than enhancing for the binding of
GMP.
Effect of Double and Triple PDE2A GAF-B Mutants on Nu-
cleotide Specificity—The previous data suggest that all the
residues that interact with the pyrimidine ring are required for
cyclic nucleotide discrimination and that loss of any one resi-
due is sufficient to lose specificity. To investigate the hypothe-
sis that combinations of changes to the Phe-438, Asp-439, and
Thr-488 binding sites might alter cAMP/cGMP specificities in a
manner that even reversed selectivity, a number of double and
TABLE I
Primers used in mutagenesis reactions
Residue change Primer direction PDE2A primer sequence
S424A Forward 5-GCA GAG ATC TGC GCA GTG TTC CTG CTG-3
S424A Reverse 5-CAG CAG GAA CAC TGC GCA GAT CTC TGC-3
F438A Forward 5-GTG GCC AAG GTG GCC GAT GGT GGC GTT GTG-3
F438A Reverse 5-CAC AAC GCC ACC ATC GGC CAC CTT GGC CAC-3
F438D Forward 5-GTG GCC AAG GTG GAC GAT GGT GGC GTT GTG-3
F438D Reverse 5-CAC AAC GCC ACC ATC GTC CAC CTT GGC CAC-3
F438E Forward 5-GTG GCC AAG GTG GAG GAT GGT GGC GTT GTG-3
F438E Reverse 5-CAC AAC GCC ACC ATC CTC CAC CTT GGC CAC-3
F438Q Forward 5-GTG GCC AAG GTG CAG GAT GGT GGC GTT GTG-3
F438Q Reverse 5-CAC AAC GCC ACC ATC CTG CAC CTT GGC CAC-3
F438Y Forward 5-GTG GCC AAG GTG TAC GAT GGT GGC GTT GTG-3
F438Y Reverse 5-CAC AAC GCC ACC ATC GTA CAC CTT GGC CAC-3
D439A Forward 5-GCC AAG GTG TTC GCT GGT GGC GTT GTG-3
D439A Reverse 5-CAC AAC GCC ACC AGC GAA CAC CTT GGC-3
D439H Forward 5-GCC AAG GTG TTC CAT GGT GGC GTT GTG-3
D439H Reverse 5-CAC AAC GCC ACC ATG GAA CAC CTT GGC-3
D439N Forward 5-GCC AAG GTG TTC AAT GGT GGC GTT GTG-3
D439N Reverse 5-CAC AAC GCC ACC ATT GAA CAC CTT GGC-3
D439P Forward 5-GCC AAG GTG TTC CCG GGT GGC GTT GTG-3
D439P Reverse 5-CAC AAC GCC ACC CGG GAA CAC CTT GGC-3
A459S Forward 5-GAC CAA GGC ATC AGC GGC CAC GTG GCG-3
A459S Reverse 5-CGC CAC GTG GCC GCT GAT GCC TTG GTC-3
A459T Forward 5-GAC CAA GGC ATC ACC GGC CAC GTG GCG-3
A459T Reverse 5-CGC CAC GTG GCC GGT GAT GCC TTG GTC-3
V484T Forward 5-CTT TTC TAT CGC GGC ACC GAT GAC AGC ACT G-3
V484T Reverse 5-C AGT GCT GTC ATC GGT GCC GCG ATA GAA AAG-3
D485A Forward 5-C TAT CGC GGC GTA GCG GAC AGC ACT GGC-3
D485A Reverse 5-GCC AGT GCT GTC CGC TAC GCC GCG ATA G-3
T488A Forward 5-GTA GAT GAC AGC GCT GGG TTC CGC ACA CGC-3
T488A Reverse 5-GCG TGT GCG GAA CCC AGC GCT GTC ATC TAC-3
T492A Forward 5-GC ACT GGG TTC CGC GCG CGC AAC ATT CTC-3
T492A Reverse 5-GAG AAT GTT GCG CGC GCG GAA CCC AGT GC-3
E512A Forward 5-GTC ATT GGT GTG GCT GCG CTA GTG AAC AAG-3
E512A Reverse 5-CTT GTT CAC TAG CGC AGC CAC ACC AAT GAC-3
N515A Forward 5-GCT GAG CTA GTG GCC AAG ATC AAT GGG-3
N515A Reverse 5-CCC ATT GAT CTT GGC CAC TAG CTC AGC-3
K516A Forward 5-GAG CTA GTG AAC GCG ATC AAT GGG CCA TGG-3
K516A Reverse 5-CCA TGG CCC ATT GAT CGC GTT CAC TAG CTC-3
K516D Forward 5-GAG CTA GTG AAC GAT ATC AAT GGG CCA TGG-3
K516D Reverse 5-CCA TGG CCC ATT GAT ATC GTT CAC TAG CTC-3
F522A Forward 5-C AAT GGG CCA TGG GCT AGC AAG TTT GAT G-3
F522A Reverse 5-C ATC AAA CTT GCT AGC CCA TGG CCC ATT G-3
D526A Forward 5-GG TTC AGC AAG TTT GCT GAG GAC CTG GCC-3
D526A Reverse 5-GGC CAG GTC CTC AGC AAA CTT GCT GAA CC-3
D526K Forward 5-GG TTC AGC AAG TTT AAA GAG GAC CTG GCC-3
D526K Reverse 5-GGC CAG GTC CTC TTT AAA CTT GCT GAA CC-3
E527A Forward 5-C AGC AAG TTT GAT GCC GAC CTG GCC ACA G-3
E527A Reverse 5-C TGT GGC CAG GTC GGC ATC AAA CTT GCT G-3
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triple mutants were created in PDE2A GAF-B. F438D, F438E,
and D439H substitutions were used in some of the double and
triple mutants, because their single mutations gave slightly
larger cAMP/cGMP ratio shifts than the alanine mutations. All
the double and triple mutants had IC50 values similar to the
individual single mutations (Table III), and the cAMP and
cGMP competition curves become nearly superimposable.
Thus, the effect of the double and triple mutants at the binding
site appears to mimic the changes in binding caused by any of
the single mutations to Phe-438, Asp-439, or Thr-488.
Phosphate-ribose Moiety and Imidazole Ring Contacts Are
Critical for cGMP Binding—The crystal structure of PDE2A
GAF-A/B with cGMP bound shows the residues that define the
binding pocket (Fig. 2B) (9). The relative importance of those
amino acids that make close contact with the cyclic nucleotide
in PDE2A GAF-A/B were investigated by mutating each to
alanine and the affinity and specificity of the resultant proteins
for both cAMP and cGMP were measured (Table II). Most of
these mutant proteins could be isolated on a cGMP affinity
column, and therefore were presumably folded correctly. Those
that did not bind to the affinity column were investigated after
purification on Talon resin and size exclusion chromatography.
Individual alanine substitutions of each residue that interacts
with the phosphate-ribose moiety (Ala-459, Val-484, Asp-485,
Thr-492, and Glu-512) or imidazole ring (Ser-424) resulted in a
decrease of cyclic nucleotide binding to below detectable levels
(Table II).
NKFDE Motif Is Required for cGMP Binding—Because the
FIG. 3. SDS-PAGE of the expressed wild-type and mutant
PDE2A GAF-B, GAF-A/B, and GAF-A/BC used in these studies.
Pooled samples (1–3 g) from wild-type or mutant enzymes, purified
through the Superose® 12 column as described under “Experimental
Procedures,” were applied to each lane. Proteins were visualized with
Coomassie Brilliant Blue staining dye. The molecular masses in kilo-
daltons of protein standards (Bio-Rad) are indicated on the right. A,
lanes 1–4, PDE2 GAF-B; lane 1, wild-type; lane 2, wild-type PDE2
GAF-A/B; lane 3, F438A mutant; lane 4, D439A mutant; lane 5, T488A
mutant. B, lanes 1–4, GAF-A/BC; lane 1, A459S mutant; lane 2,
K516A mutant; lane 3, F522A mutant; lane 4, wild-type; lane 5, molec-
ular weight standards. Rectangles outline the GAF-B, GAF-A/B, and
GAF-A/BC bands.
TABLE II
Summary of cAMP and cGMP binding affinities for various GAF domain mutants
The values are the average of three or four experiments  S.D. Various concentrations of either unlabeled cGMP or cAMP were used as
competitive substrates to inhibit the binding of radiolabeled cGMP to purified mouse PDE2A GAF-A, GAF-A/B, GAF-A/BC, and bovine
holoenzyme, and PDE2A GAF-A/B mutants. Labeled ligand concentration was 1 nM, and protein concentration was 0.6 nM. Data shown are
representative of experiments performed three times, and values are mean  S.E. of triplicate determinations.
Amino acid residue change
IC50




GAF-A ND ND ()a
GAF-B 146  10 7  1 20.9 
GAF-A/B 247  14 25  2 9.9 
GAF-A/BC 400  20 20  2 20.0 
Holoenzyme 598  47 22  1 27.2 
Pyrimidine ring-binding residues (GAF-A/B)
F438A 82  3 61  12 1.3 
D439A 46  13 61  3 0.8 
D439N 131  27 28  11 4.7 
D439P 158  32 152  31 1.0 
T488A 30  5 38  2 0.8 
Phosphate-ribose and imidazole ring-
binding residues (GAF-A/B)
S424A NDb ND 
A459S ND ND 
A459T ND ND 
V484T ND ND 
D485Ac ND ND 
T492A ND ND 
E512A ND ND 
NKFDE motif residues (GAF-A/B)
N515A ND ND ()
K516A ND ND ()
K516D ND ND ()
F522A ND ND ()
D526A ND ND ()
D526K ND ND ()
E527A ND ND ()
K516D/D526K ND ND ()
a   0.3 g/l;   0.1–0.3 g/l;   0.01–0.1 g/l; and ()  	0.01 g/l (protein concentration estimates are based on intensity
of SDS-PAGE gels stained with Coomassie Blue, compared to known amounts of BSA standard).
b ND, not detectible (indicates the protein sample did not bind detectable levels of cyclic nucleotide).
c Asp-485 binds both the guanine ring and the phosphate-ribose moiety.
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NKFDE motif residues are conserved within many mammalian
PDE and Anabaena adenylyl cyclase GAF domains, it has been
predicted that this motif is directly involved in binding cyclic
nucleotides. However, in the PDE2A crystal structure, the NK-
FDE motif is found away from the binding pocket (9). Thus, we
sought to determine whether these residues play a role in
cGMP binding to PDE2A, as has been suggested in PDE5A
(13). All five NKFDE residues of PDE2A GAF-B were changed
to alanine individually, and the mutants were tested for cGMP
binding. Isolation of these proteins required use of the His6
tags and purification using Talon resin, because none of them
bound to the cGMP affinity resin. When tested by filter binding
assay, none of these mutant proteins bound cGMP at detectable
levels (Table II). To test if the Lys-Asp salt bridge stabilized a
conformation that allows cGMP to bind in the binding pocket,
three mutants were created: NDFDE (K516D), NKFKE
(D526K), and NDFKE (K516D/D526K), where the Lys and Asp
residues were switched for each other. None of these three
mutants bound cGMP at detectable levels (Table II), suggest-
ing that each prevented the proper formation of the cGMP
binding pocket in PDE2. These results differ from the effects of
a similar mutation in PDE5 where much smaller decreases in
cGMP binding affinity were seen (13).
GAF-A and the Catalytic Domain Alter cGMP Binding Affin-
ity to GAF-B of PDE2A—PDE2A is composed of an N-terminal
domain, tandem GAF domains (A and B), and a C-terminal
catalytic domain (C) (Fig. 1). As shown in Table II, mouse
PDE2A GAF-A/B binds cGMP with an IC50 of 25  2 nM, or as
much as 40 times lower than previously reported for the bovine
FIG. 4. Binding analysis for cAMP
and cGMP to PDE2A GAF-A/B. Vari-
ous concentrations of either unlabeled
cGMP (circles, solid lines) or cAMP
(squares, dotted lines) were used as com-
petitive substrates to inhibit the binding
of radiolabeled cGMP to the purified
PDE2A GAF-A/B wild-type, F438A,
D439A, and T488A. IC50 values are given
in nanomolar values. Labeled ligand con-
centration was 1 nM, and the protein con-
centration was 0.6 nM. The data shown
are representative of experiments per-
formed three times, and values are
mean  S.E. of triple determinations.
TABLE III
Binding analysis for non-alanine substitutions and double/triple
mutants of PDE2A GAF-B
Various concentrations of either unlabeled cGMP or cAMP were used
as competitive substrates to inhibit the binding of radiolabeled cGMP to
the purified mouse PDE2A GAF-B wild type and mutants. Labeled
ligand concentration was 1 nM, and protein concentration was 0.6 nM.
Data shown are representative of experiments performed three times,
and values are mean  S.E. of triplicate determinations.




B Wild type 146  10 7  1 21
B F438D 19  3 21  2 0.9
B F438E 14  3 19  11 0.7
B F438Q 28  5 25  8 1.1
B F438Y 21  2 33  7 0.7
B D439H 61  9 41  2 1.5
B F438D/D439A 18  3 33  6 0.6
B F438D/D439N 19  2 24  3 0.8
B F438E/D439A 19  4 37  8 0.5
B F438E/D439N 20  5 41  12 0.5
B F438E/T488A 45  8 34  6 1.3
B D439H/T488A 33  7 44  7 0.8
B F438E/D439A/T488A 57  2 37  6 1.5
Cyclic Nucleotide Binding and Specificity of PDE2A GAF-B 37933
 at R









PDE2A1 holoenzyme (34, 35). In the holoenzyme, binding of
cGMP to the allosteric GAF-B region results in activation of the
catalytic domain, as shown by a greater than 10-fold increase
in activity (36–39). To test the hypothesis that the presence of
the catalytic and N-terminal domains would affect cGMP bind-
ing to GAF-B, the holoenzyme and a number of GAF domain
proteins were expressed, and binding affinities measured un-
der exactly the same conditions as for the GAF-B domain alone.
Mouse PDE2A, GAF-A, GAF-B, GAF-A/B, and GAF-A/BC
were expressed in bacteria as described under “Experimental
Procedures.” The catalytic activity of the baculovirus-expressed
bovine PDE2A1 holoenzyme (60  4 mol/min/mg at 40 M
cGMP substrate) agreed reasonably well with values reported
in the literature for pure enzyme isolated from heart or adrenal
gland (32). Purified PDE2A GAF-A does not bind either cAMP
or cGMP at detectable levels (Table II), which is consistent with
the crystal structure that showed cGMP bound to only the
GAF-B domain of PDE2A GAF-A/B (9). The cGMP IC50 value
for GAF-B (7 1 nM) is3-fold less than GAF-A/B (25 2 nM),
GAF-A/BC (20  3 nM), or the holoenzyme (22  1 nM) (Fig.
5). The cAMP IC50 value for GAF-B (146  10 nM) is almost
2-fold less than GAF-A/B (247  14 nM), 3-fold less than GAF-
A/BC (400  20 nM), and 6-fold less than the holoenzyme
(598  47 nM) (Fig. 5). Thus, the presence of GAF-A appears to
decrease both cAMP and cGMP affinity, whereas the N termi-
nus and catalytic domain appear to have a further effect to
diminish cAMP but not cGMP affinity.
GAF-B Mutations Do Not Greatly Affect Global Stability or
Global Folding—It was possible that the effects of some of the
mutations described previously were due to effects on the sta-
bility or global folding of the expressed proteins. We were
particularly worried about the mutations made in the NKFDE
region and those in close contact with the ribose moiety as they
showed no cGMP binding. Therefore, we developed a GAF-A
plus GAF-B plus catalytic domain bacterial expression vector
(GAF-A/BC). This allowed the effects of mutations on more
than one functional domain to be measured. Interestingly, the
specific catalytic activity (Vmax) of the bacterially expressed
A/BC wild-type construct was very high, in fact by as much as
4 times higher than the highest activity reported in the liter-
ature for any native holoenzyme (2, 6). As shown in Table IV,
the A459S, K516A, or F522A mutations on A/BC abolished
high affinity cGMP binding as they did in the isolated GAF
domains alone. However, each of these constructs still had high
catalytic activity (25–55% of recombinant wild-type A/BC and
100% of the value reported for holoenzyme purified by classic
procedures from bovine heart). Therefore, it appears that the
mutations did not cause a global denaturation of the protein.
DISCUSSION
Roles of Phe-438, Asp-439, and Thr-488 in GAF-B of
PDE2A—Phe-438, Asp-439, and Thr-488 appear to control nu-
cleotide specificity in the PDE2A GAF-B binding site. The
mutation F438A in PDE2A GAF-A/B changed the wild-type
FIG. 5. Binding analysis for cAMP
and cGMP binding to holoenzyme
GAF domain proteins. Various concen-
trations of either unlabeled cGMP (circles
and solid lines) or cAMP (squares and dot-
ted lines) were used as competitive sub-
strates to inhibit the binding of radiola-
beled cGMP to the purified mouse PDE2A
GAF-B, GAF-A/B, GAF-A/BC, and bo-
vine holoenzyme. IC50 values are given in
nanomolar values. Labeled ligand concen-
tration was 1 nM, and the protein concen-
tration was 0.6 nM. The data shown are
representative of experiments performed
three times, and values are mean  S.E.
of triplicate determinations.
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IC50 values from 247  14 nM to 82  3 nM for cAMP and from
25  2 nM to 61  12 nM for cGMP. Therefore, the ability of
GAF-B to discriminate between cGMP and cAMP clearly relies
at least in part on residue Phe-438. The crystal structure of
PDE2A GAF-A/B shows that the side chain of Phe-438 is base-
stacked with the guanine ring (Fig. 2B) (9). Stacking interac-
tions are common in many nucleotide-binding domains. For
example, in the crystal structure of glycogen phosphorylase,
aromatic amino acids in the binding sites base stack with the
adenine rings of AMP and NADH (27). It has been postulated
from analog studies that there is a difference in polarization
potential of the purine ring of cAMP versus cGMP toward the
polarizable amino acid side. Because the magnitude and direc-
tion of the dipole moment of the purine ring in cGMP is signif-
icantly different than in cAMP, the guanine base would be
expected to have different dipole-induced dipole interactions
with the polarizable Phe-438 (40). These differences have been
used to explain catalytic specificity preferences for cyclic nu-
cleotide analogs at the PDE2 catalytic site (39, 40). Actually,
because these studies were conducted with PDE2 holoenzyme
and we now know that the GAF domains can regulate the
activity of the catalytic domain of the enzyme, it may be that
the measured catalytic activities were in part due to differences
in GAF domain binding of the analogs. Regardless of whether
the changes seen with these early studies were due to GAF
domain or catalytic domain binding, the changes in IC50 values
seen in PDE2A GAF-B with the replacement of F438Y suggest
such a mechanism may hold. F438Y shows a similar cAMP and
cGMP IC50 shift as that of the alanine mutation to that site,
presumably due to a preferred solvent-stabilized orientation of
the polar side chain of tyrosine that does not allow for base-
stacking interactions with tyrosine.
D439N contains a side-chain amide group in place of a car-
boxylate but still retains the ability to hydrogen bond to N-1 of
cGMP, likely explaining its similar cGMP affinity as wild-type.
The asparagine presumably can still act to exclude cAMP,
because its steric character mimics aspartate, unlike alanine,
which has a much smaller methyl group side chain. D439P
removes the potential for a hydrogen bond to form between the
Asp-439 backbone amide group and the guanine ring carbonyl
at C-6, which would be expected to decrease cGMP affinity. On
the other hand, this mutation also should eliminate a clash
with the amino group at C-6 of cAMP allowing for increased
cAMP binding.
Alanine mutations of Asp-439 and Thr-488 also remove hy-
drogen bonding potential for cGMP, likely explaining the 2-
fold increase in IC50 for cGMP (Fig. 6, A and B). The IC50 for
cAMP is decreased nearly 8-fold by D439A, presumably by
removing a polar side-chain clash with the N-1 nitrogen group
of cAMP (Fig. 6, C and D). With more bulk solvent exposure of
HOH1, T488A also may reduce this clash by allowing the
adenine ring to move away from the Asp-439 backbone amide.
In the double and triple mutants of Phe-438, Asp-439, and
Thr-488, the Asp-439 side-chain clash would probably be re-
duced to the same level as with a single mutation. This likely
explains why the effects of the individual mutations were not
additive. Interestingly, the multiple alanine mutations did not
prevent the cyclic nucleotide from being stabilized in the bind-
ing pocket and still allowed for high affinity cGMP binding.
PDE2A GAF-B: An Alternate Model for Nucleotide Selectiv-
ity—PDE2A GAF-B offers a new model for high affinity gua-
nine nucleotide binding where three residues are all required
to interact together to determine cyclic nucleotide selectivity
(Fig. 7, A and B). This differs from other high affinity guanine
nucleotide-binding proteins, such as a membrane guanylate
cyclase (RetGC-1) and rod cyclic nucleotide-gated ion channels,
where a single carboxylate of a glutamate or an aspartate,
respectively, interact with both N-1 and N-2 of the guanine ring
(Fig. 7, C and D) (17, 20). In the bovine rod cyclic nucleotide-
gated ion channel, the substitution by a non-polar residue of
the single aspartate residue in the binding domain signifi-
cantly inverted nucleotide selectivity in favor of cAMP by re-
moving unfavorable electrostatic interactions with the free
electron pair of N-1 (17). This type of interaction between the
guanine ring and an aspartate residue in the rod cyclic nucle-
otide-gated ion channel is identical to that shown in other high
affinity GTP-binding proteins such as transducin- (22), EF-Tu
(21), and H-ras p21 (23). Neutralization of the analogous as-
partate residue in H-ras p21 (41) and EF-Tu (42) also resulted
in decreased nucleotide selectivity. Thus, although a general
precedent exists for a role of aspartate or glutamate on nucle-
otide selectivity, the natures of the interactions vary greatly
among different proteins.
In PDE2A GAF-B, Asp-439 also makes a similar hydrogen
bond to N-1 with its carboxylate; however, it does not bind to N-2.
This allows the other two residues to interact with the guanine
ring through a water molecule or base stacking. Thus, Phe-438,
Asp-439, and Thr-488 all must be present to achieve the selec-
tivity found in the GAF-B binding site. Furthermore, unlike
other cyclic nucleotide binding sites, cGMP is bound in its ex-
tended, anti-conformation, and the phosphate group of cGMP is
stabilized in part by the dipole of helix 3 (9). Therefore, PDE2A
GAF-B offers an alternative model for high affinity guanine nu-
cleotide binding by demonstrating how multiple residues may act
in concert to control nucleotide discrimination.
Mechanism of Cyclic Nucleotide Binding—The data pre-
sented suggest that the residues contacting the phosphate-
ribose moiety are absolutely required for high affinity cGMP
binding to the GAF-B domain. Val-484 makes van der Waals
contact with the ribose ring, and its replacement with a thre-
onine abolishes cGMP binding. If this side chain rotates 90°,
the hydroxyl group from the threonine would be better exposed
to solvent, but this is apparently overridden by the fact that the
-methyl group would then clash with the ribose ring oxygen
(Fig. 2B). Even mutations to serine or threonine of Ala-459, a
residue that makes backbone contacts to the phosphate-ribose
moiety, abolish cGMP binding. The C of Ala-459 is buried
within the binding pocket and is in close proximity with Glu-
512 (Fig. 2, B and C). Thus, the hydrophilic hydroxyl groups on
serine and threonine may disturb packing in the region, dis-
place HOH3, or form hydrogen bonds with the OE1 of Glu-512.
Any of these factors individually or in concert may explain the
apparent loss of cGMP binding seen in this mutant.
Asp-485 is another binding pocket residue where an alanine
mutation abolishes binding. The side chain of Asp-485 forms a
3.2-Å hydrogen bond contact with HOH1 that binds to the
TABLE IV
Specific activity and binding affinities of PDE2A “A/BC” constructs
isolated from the final sizing column
Values are the averages of duplicate experiments plus or minus the
range. Corrections for purity were made based on analysis using
ImageJ® from Coomassie Blue-stained SDS-PAGE gels.







A459S 38.6  7.2 271  68 NDa
K516A 18.2  1.1 135  22 ND
F522A 16.6  0.2 132  11 ND
ABC WT 68.1  1.1 404  49 53.2  4.1
Wild-type holoenzymeb 120
a ND, not determined.
b Value taken from Martins et al. (32).
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pyrimidine ring and forms a van der Waals contact with HOH2
that binds to the ribose ring (9). The backbone amide of Asp-
485 forms a 3.0-Å hydrogen bond contact also with HOH2 that
binds to the ribose ring (Fig. 2C) (9). Thus, D485A removes the
side chain and van der Waals contacts, which would likely
perturb the hydrogen bonds mediated by the two waters and
cause the loss of cGMP binding seen in this mutant.
The complete loss of cGMP binding observed for mutations at
residues that interact with the phosphate-ribose moiety of
cGMP suggests that the majority of the energetic contribution
for binding may be attributed to the phosphate-ribose ring-
binding residues, which stabilize the nucleotide-bound form of
the enzyme. In studies on the bovine rod cyclic nucleotide-gated
ion channel, the closed channel also has been suggested to bind
the cyclic nucleotide primarily through its ribose and phos-
phate (17). In this channel, the purine ring of the cyclic nucle-
otide does not appear to be important for initial binding to the
channel, but rather its interactions with the side chain of an
aspartate in the binding site appear to control the allosteric
conformational change leading to channel opening (17). Thus, a
significant portion of the binding energy residing within the
bonds formed between the nucleotide ribose and phosphate and
the binding pocket residues may be a widespread mechanism
by which many high affinity guanine nucleotide-binding pro-
teins stabilize cyclic nucleotides within their binding sites. It
was surprising that a single alanine mutation within the bind-
ing pocket could abolish binding. These mutations may have
affected the local folding of the protein, or perhaps disturbed
a network of hydrogen bonds making the protein sensitive to
the removal of one of them. Such hydrogen bond networks that
are sensitive to single changes have been discussed previously
(43, 44).
NKFDE Motif May Link GAF-B and the Catalytic Domain—
Initially it was a great surprise to find that none of the NKFDE
residues of GAF-B are in contact with cGMP, because they
were conserved in most cGMP-binding PDEs and because mu-
tation of the NKFDE reduced binding in PDE5. Therefore, it
was important to determine the effects of mutations to these
residues in PDE2. Again, somewhat unexpectedly, mutations
to these residues completely abolished cGMP binding. From
the crystal structure, it seemed possible that mutations of the
NKFDE motif may disrupt interactions between Glu-512 and
cGMP, as Glu-512 is near Asn-515, at the beginning of the
motif. Glu-512 is a critical residue in the binding pocket (Table
II). It also seems possible that the substitutions NDFDE
(K516D) and NKFKE (D526K) would disrupt the salt bridge
within the NKFDE motif and that this bridge is required for
cyclic nucleotide binding (Fig. 2A). Moreover, the NDFKE
(K516D/D526K) result further suggests that the order of the
residues, Lys followed by Asp, is essential. It remains a possi-
bility that the lack of binding seen in the NKFDE mutants is
because this motif is essential for correct folding and nothing
else. However, the data with the A/BC construct would argue
against this possibility. Because the catalytic activity of these
constructs remained largely intact, the mutations clearly did
not introduce a large global change in the protein. The fact that
the specific activity is higher than the wild-type may suggest
that some part of the molecule, presumably the N-terminal
region, normally inhibits catalytic activity. However, this hy-
pothesis will take further experimentation to test rigorously.
Why the NKFDE motif is so well conserved and absolutely
required for binding in PDE2A clearly deserves further inves-
tigation but may require crystallization to solve.
Differential Effects of cAMP and cGMP—Evidence in the
literature suggests that, in PDE2A, cAMP and cGMP induce
different conformations. For example, chemical modification of
PDE2A with dicyclohexylcarbodiimide partially activates the
enzyme but only in the presence of cGMP, not cAMP, suggest-
ing that the cGMP-induced conformational changes are differ-
FIG. 6. D439A mutation removes cyclic nucleotide selectivity
of the GAF-B domain in PDE2A. cGMP and cAMP (the cognate
ribose and cyclic phosphate portions are not shown) are modeled into
the binding site of PDE2 GAF-B with residues and hydrogen bonding
shown (A and C). Removal of the aspartate side chain (D439A) reduced
the favorable interactions with cGMP at N-1 while eliminating one
repulsive interaction (X) with cAMP (B and D). Phe-438 (not shown)
base stacks with the guanine ring of cGMP.
FIG. 7. Hypothesis for purine selectivity by the GAF-B domain
on PDE2A. cAMP and cGMP (cognate ribose and cyclic phosphate
portions not shown) are modeled into the binding site of PDE2 GAF-B.
The difference in affinity between cGMP and cAMP binding to PDE2A
GAF-B appears due to three positive interactions (N-1, N-2, and O-6)
with cGMP (A) and two negative interactions (N-1 and N-6) with cAMP
(B), as well as differences in stacking interactions with Phe-438. This
differs from other high affinity guanine nucleotide-binding proteins,
where a carboxylate group bonds with the N-1 and N-2 of cGMP (C)
while it is repulsed by the free electron pair of N-1 in cAMP (D).
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ent from cAMP-induced changes (6). In earlier studies, the
cGMP-bound enzyme was shown to be more susceptible to
chymotrypsin inactivation than the cAMP-bound enzyme (6,
45). The major chymotrypic cleavage site exposed by cGMP
binding is at tyrosine 553 (6), which is found in the 5 helix of
GAF-B, implying that this region takes part in the conforma-
tional change. These findings further suggest that cGMP bind-
ing to the GAF-B domain creates a ligand-dependent confor-
mational change that is transmitted mechanically, to expose
the 5 helix to chymotrypsin inactivation, or the enzyme to
dicyclohexylcarbodiimide modification and activation. A simi-
lar mechanism of activation has been suggested to occur in the
guanine nucleotide exchange protein directly activated by
cAMP (Epac), where binding of cAMP transmits a conforma-
tional change via a “hinge” to induce a structural change in the
C-terminal portion of the protein (46). Taken together, these
findings support the notion that both cAMP and cGMP bind
GAF-B but transmit distinct conformational changes to the
catalytic part of the enzyme. Therefore, it was not too surpris-
ing in the current studies that specific point mutations could
differentially alter cAMP and cGMP binding affinity.
High Affinity of PDE2A—An initially surprising finding was
that the individual GAF domain constructs bound cGMP with
very high affinity, in fact much higher than initially reported
for the PDE2 holoenzyme. It seemed possible that microscopic
reversibility might in part explain the decrease in binding
affinity in the holoenzyme due to the presence of the catalytic
domain, because cGMP binding to GAF-B and activation of the
catalytic domain are coupled. A tighter cyclic nucleotide bind-
ing affinity in individual GAF domains relative to the tandem
GAF domains or holoenzyme have also been reported recently
in PDE5A (16). Thus, neighboring domains may weaken the
binding affinity in other mammalian PDE GAF domains. In the
present studies, the neighboring GAF-A and catalytic domains
appear to have an additive affect on the IC50 values for cAMP
but not cGMP binding to GAF-B (Table II). Again, the complete
explanation for these differences will probably require a crystal
structure for the holoenzyme in the bound and unbound state.
The apparent cAMP and cGMP binding affinities reported
here for all the PDE2A GAF domain proteins, including the
holoenzyme, are substantially higher than those previously
reported (6, 32, 34, 36, 47). This is likely, because the assays
performed in this study used very low protein concentrations
(1 nM). In order for the IC50 value to approach Ki, the level of
protein in the assay must be substantially less than the Kd of
the radioligand.2 Most if not all of the previously reported
cAMP and cGMP binding affinity studies have been performed
at much higher protein concentrations or used cell extracts
where the exact enzyme concentration was unknown (6, 32, 34,
36, 47). In retrospect, it can be calculated that nearly all of
these earlier studies did not meet the normal Michaelis-Men-
ten assumption that the concentration of the ligand be much
higher than the binding protein. Therefore, for high affinity
binding sites, this would have resulted in an apparent titration
until ligand levels started to exceed protein concentration. Ex-
perimentally, in the present studies when the protein concen-
tration was decreased, lower IC50 values for cGMP for the
wild-type enzyme were observed. Thus, previously reported
cGMP affinities for PDE2A (6, 32, 34, 36, 47) are likely to be
artificially low due to this effect. Another formal possibility,
however, is that the higher dilutions used in the current stud-
ies cause a dilution-induced disaggregation of PDE2 to a form
that has a higher intrinsic binding affinity.
Regardless of the reason, the question arises as to the pos-
sible physiological consequences of such high affinity sites. In
many tissues with high local concentrations of PDE2A, such as
brain, adrenal gland, and olfactory cilia, enzyme levels are
likely to be quite high, well above “basal” cGMP concentrations
(5, 49, 50). Under these conditions, where the GAF domains
would not be fully occupied, the high affinity binding site on
PDE2A would be expected to function as a fast, sensitive, “on”
switch for PDE2 when cGMP is increased. The off-rate of the
switch would then be determined by the off-rate of the nucle-
otide from the GAF domain.
Examples of very rapid cyclic nucleotide changes have been
seen in olfactory neurons (51), astrocytes and strial cells (52),
platelets (53, 54), and the heart (55), all of which are known to
contain high levels of PDE2A. Such a fast response to cGMP
could clearly be related to the rapid activation of PDE2 caused
by cGMP binding to the GAF-B domain. If the GAF domains
are as exquisitely sensitive to cyclic nucleotide concentrations
in intact tissues as in these in vitro studies and no other factors
in the cell are identified that modulate cGMP affinity, we may
need to re-evaluate our ideas about regulation of this enzyme in
physiological situations.
Finally, these studies raise questions about the mechanisms
by which cyclic nucleotide binding to the GAF-B domain is
allosterically coupled to changes in activity at the catalytic site.
This is especially true, because the concentrations of cyclic
GMP that allosterically activate the holoenzyme in vitro are
much higher than the cGMP affinity constants determined in
this study. A complete analysis of the effects of the mutations
described in the present study on the PDE2 holoenzyme as well
as mutations at the dimerization interfaces and likely in the
catalytic domain will probably be needed to fully address this
problem. Ultimately, it likely will require solution of the struc-
ture of the holoenzyme to know where to begin these studies.
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the denominator would in all cases be very close to 1, and the IC50 value
will closely approximate Ki.
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